Suny Downstate Health Sciences University

Brooklyn, New York 11231

3 studies enrolling now · 15 studies all time

What they study most

Active Nonsegmental Vitiligo, Atopic Dermatitis, COVID-19, Cardiovascular Diseases, Chronic Kidney Disease, Covid19, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip, Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Dermatological Non-Disease

Studies at this site

• Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease — Recruiting now
• Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer — Recruiting now
• Rare and Atypical Diabetes Network — Recruiting now
• A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children — Completed
• A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo — Running, not enrolling
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
• A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo — Completed
• Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists — Running, not enrolling
• The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. — Stopped early
• Combination Facial Aesthetic Treatment in Millennials — Completed
• Pimavanserin for Sleep in Parkinson Disease — Withdrawn before enrolling
• Light Treatment Effectiveness (LITE) Study — Completed
• Web Based Orthopaedic Sports Medicine Registry — Stopped early
• Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19 — Stopped early
• Positive Affect Promotion to Empower Optimal Adherence to HIV Therapy — Completed